Skip to content
SEKISUI XenoTech DD Blog Logo

Big Hepatocyte News!

As you may have heard, SEKISUI XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS” for its CryostaX® hepatocytes. The single-freeze preparation process minimizes cryoinjury, promoting high viability, cell yield and enzymatic activity for long-term consistent test results. Additionally, the resulting “pellets” do not require thawing to be pooled or used. CryostaX®  donors can be selected individually or custom pooled at no additional cost from over 200 options for specific enzyme activities, yield, pool size or donor BMI, disease state, age, ethnicity, gender, substance use, serology, etc. Lots are available for suspension or plating

The announcement also included several other important updates, such as the implementation of technology and methodology improvements over the last year which resulted in 20-40% higher cell yield and almost 10% higher viability. Furthermore, the company renegotiated its donated liver contract for access to 3.5 times more livers, allowing the selection of higher quality tissue and specific demographics. SEKISUI XenoTech also began providing certificates of quality and sterility for its hepatocyte media… 

Read More

Learn more about:

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment
005 International Messaging Created with Sketch.

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate